Update on stents: Recent studies on the TAXUS® stent system in small vessels by Tanimoto, Shuzou et al.
© 2007 Dove Medical Press Limited.   All rights reserved
Vascular Health and Risk Management 2007:3(4) 481–490 481
REVIEW
Update on stents: Recent studies on the TAXUS® 




Thoraxcenter, Erasmus Medical 
Center, Rotterdam, The Netherlands
Correspondence: Patrick W Serruys
Thoraxcenter, Ba-583, Dr. Molewaterplein 
40, 3015 GD, Rotterdam, The Netherlands
Tel +31 10 463 5260
Fax +31 10 436 9154
Email p.w.j.c.serruys@erasmusmc.nl
Abstract: Small vessel size ( 3 mm) has been identiﬁ  ed as an independent predictive factor 
of restenosis after percutaneous coronary intervention when using bare metal stents (BMS). It 
remains controversial whether BMS placement in small vessels has an advantage over balloon 
angioplasty in terms of angiographic and clinical outcomes. The advent of drug eluting stents 
(DES), either paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES), has strongly 
impacted interventional cardiology by signiﬁ  cantly reducing restenosis and the need for repeat 
revascularization. Therefore, it was also expected that DES could substantially reduce restenosis 
in smaller vessels. However, even in the DES era, small vessel size remains an independent 
predictor of angiographic and clinical restenosis. To date, only a few studies systematically 
investigate the clinical effect of DES placement in small vessels. In addition, some potential 
issues with the use of DES have been raised, such as late stent thrombosis and late restenosis. 
In order to (i) establish the superiority of DES over BMS; (ii) verify the efﬁ  cacy and safety 
of DES; and (iii) critically assess the superiority of one DES over the other in patients with 
small coronary arteries, further multicenter, randomized clinical trials with larger sample size 
are warranted.
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Introduction
Percutaneous coronary intervention (PCI) is a major treatment strategy for patients 
with coronary artery disease (CAD), and currently coronary stents are widely 
used in the world (Brophy et al 2003). As compared to balloon angioplasty, bare 
metal stents (BMS) prevent both early elastic recoil and late vascular remodeling. 
These abilities of BMS reduce coronary restenosis and significantly improve the 
angiographic and clinical outcomes in vessels with a reference vessel diameter 
(RVD) typically more than 3 mm as assessed by quantitative coronary angiogra-
phy (QCA) (Serruys et al 1994; Fischman et al 1994; Macaya et al 1996; Betriu 
1999; Kiemeneij 2001). On the contrary, in terms of stent implantation in vessels 
with a RVD = 3 mm, several randomized trials have failed to show an advantage 
of BMS over balloon angioplasty (Kastrati et al 2000; Park et al 2000; Koning 
et al 2001; Moer et al 2001). A recent meta-analysis of small vessel BMS stent-
ing reported that rates of restenosis, repeat revascularization and major adverse 
cardiovascular events (MACE; defined as death, myocardial infarction (MI), and 
repeat revascularization) were 27.8 %, 14.9% and 17.6%, respectively (Agostini 
et al 2005). The high observed restenosis rate (27.8%) may be attributed to a 
comparable absolute late lumen loss after stenting in both small and large ves-
sels: a similar small volume of neointimal hyperplasia would induce a diameter 
stenosis = 50% in small vessels more easily compared to large vessels by virtue 
of their smaller RVD (Akiyama et al 1998). The higher angiographic restenosis 
rate may translate into high repeat revascularization and MACE rates in the Vascular Health and Risk Management 2007:3(4) 482
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clinical setting. In addition, small vessel size is known 
to be an independent predictive factor of restenosis after 
PCI (Bauters et al 1998; Serruys et al 1999). Therefore, 
it remains controversial whether BMS implantation in 
small vessels improves outcomes compared to balloon 
angioplasty alone. At present, however, PCI in small 
vessels with a RVD  3 mm accounts for almost 50% 
of all revascularization procedures and leads to a higher 
incidence of restenosis and adverse cardiac events (Wong 
et al 2000).
In the last 3 to 4 years, drug-eluting stents (DES), either 
sirolimus-eluting stents (SES: Cypher®; Cordis Corpora-
tion, Warren, NJ) or paclitaxel-eluting stents (PES: TAX-
US™; Boston Scientific Corporation, Natick, MA), have 
revolutionized the interventional cardiology practice by 
dramatically reducing restenosis and the need for repeated 
revascularization as compared to BMS (Moses et al 
2003; Schofer et al 2003; Schampaert et al 2004; Stone 
et al 2004a). The superiority of DES over BMS has been 
observed not only in simple lesions but also in complex 
lesions, such as chronic total occlusions, diffused long 
lesions, saphenous vein graft lesions, restenotic lesions, 
and acute coronary syndromes. Consequently, the advent 
of DES creates the expectation of reducing restenosis 
substantially in patients with small vessels.
Many clinical trials indicated DES implantation to be 
feasible and safe. However, certain potential safety issues 
of DES usage have arisen with its widespread used. Some 
recent studies have cautioned that either SES or PES could 
increase thrombotic complications compared to BMS, 
especially late stent thrombosis (occurring  30 days after 
stent placement) (McFadden et al 2004; Iakovou et al 
2005; Ong et al 2005; Moreno et al 2005). As another 
problem, delayed restenosis (occurring beyond the first 
6 to 9 months after stent placement), usually referred to 
as the “late catch-up phenomenon”, has been discussed 
emphasizing the need for long-term follow-up data. This 
complication was especially noted after brachytherapy, a 
procedure whose use has been discontinued. Since PCI in 
small vessels constitutes a more complicated treatment 
strategy than simple lesions, which leads to a higher 
incidence of adverse cardiac events after procedure, 
physicians should carefully follow patients treated with 
small vessel DES stenting.
In this review, we describe efﬁ  cacy and safety results 
from clinical trials of the TAXUS® stent system placement 
in small vessels and compare the angiographic and clinical 
outcomes of 3 direct comparison (PES vs SES) trials.
Paclitaxel and TAXUS® stent system
Paclitaxel is an anti-tumor agent used to treat several kinds 
of solid tumors, most commonly tumors of the breast and 
ovary. This drug interferes with microtubule organization by 
interrupting mitosis (M phase) and extracellular secretion. 
Microtubular dynamics regulate many of the inﬂ  ammatory 
and proﬁ  brotic steps of the restenostic cascade. Paclitaxel 
interrupts this cascade at multiple levels and inhibits cell 
proliferation and migration (Axel et al 1997; Hui et al 1998; 
Giannakakou et al 2001).
Use of the TAXUS® stent system in patients with 
CAD has been fully investigated in the TAXUS trials 
(see Table 1). Results from a total of 6 TAXUS trials have 
been reported to date (Grube et al 2003; Colombo et al 
2003; Tanabe et al 2003; Stone et al 2004a; Stone et al 2005, 
Dawkins et al 2005). Follow-up of patients in 4 TAXUS 
trials (TAXUS II, IV, V, and VI) are still ongoing as of 
the date of this review. Several versions of the TAXUS 
stent technology using different platform types (NIRx, 
EXPRESS, EXPRESS2) and drug release kinetics (slow-
release and moderate-release) but similar polymers, stent 
materials and drug concentrations (1.0 µg/mm2 of pacli-
taxel), were used among these 6 trials (see also Table 1).
The TAXUS NIRx stent was a slotted-tube stainless steel 
stent coated with paclitaxel incorporated into a slow-release 
(SR) or a moderate-release (MR) copolymer carrier system 
with biphasic drug release. The initial release is over the ﬁ  rst 
48 hours followed by SR over the next 10 days. Release kinet-
ics of the TAXUS NIRx MR stent in vivo has been shown 
to be faster than that of the TAXUS NIRx SR stent, result-
ing in a 3-fold higher in vivo drug release at 10 days. The 
TAXUS EXPRESS stent consists of a balloon-expandable 
EXPRESS stent with TRANSLUTE™ polymer-coating con-
taining paclitaxel. The TAXUS EXPRESS2 stent is composed 
of a balloon-expandable EXPRESS2 stent with a triblock 
copolymer coating with paclitaxel. This coating serves as 
a carrier to provide uniform and controlled biphasic release 
of the drug into the vessel wall. SR and MR formulations of 
the polymer are available in the TAXUS EXPRESS2 stent. 
The MR formulation also results in approximately 3-fold 
higher drug release than the SR polymer. The SR polymer 
formulation of the TAXUS EXPRESS2 stent is commercially 
available now.
PES versus BMS in small vessels
So far, no dedicated, prospective multicenter, randomized 
clinical study comparing the PES to BMS in patients with 
small vessel disease has been conducted. However, the Vascular Health and Risk Management 2007:3(4) 483
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existing PES versus BMS clinical studies have reported 
substudy results in small vessels as a subgroup analysis, thus 
restricting the interpretation of the results (see Table 2). Small 
vessel subgroup analyses from 3 of the 4 larger controlled, 
multicenter TAXUS trials are brieﬂ  y described below.
TAXUS IV trial
In the TAXUS IV trial (Stone et al 2004a, 2004b), various 
types of subgroup analyses were performed. With regard to 
vessel size, enrolled patients were divided into the following 
3 groups per RVD; = 2.5 mm,  2.5 mm to  3.0 mm and 
= 3.0 mm. In the smallest RVD group (= 2.5 mm, n = 176), 
the 9-month angiographic restenosis rate in the PES group 
was signiﬁ  cantly lower than in the BMS group (PES, 10.2% 
versus BMS, 38.5%; p   0.001). In addition, 12-month target 
lesion revascularization (TLR) rate was signiﬁ  cantly lower in 
the PES group (5.6%) as compared to the BMS group (20.6%, 
p   0.0001). Moreover, in multivariate analysis, the RVD 
was not related with 12-month TLR rate in the PES group, 
while it was an independent predictor of 12-month TLR rate 
in the BMS group. No other angiographic parameters and 
clinical outcomes in this subgroup analysis were reported 
in this trial.
TAXUS V trial
In the TAXUS V trial (Stone 2005), subgroups of patients 
with complex lesions, requiring 2.25 mm or 4.0 mm long 
stents and multiple stents ( 1 stent), were investigated. In 
the patient group treated with the 2.25 mm stent, which con-
sisted of 17.6% of total enrolled population, the mean RVD 
was 2.08 mm. Both treatment groups (PES and BMS) had 
similar acute clinical outcomes. At the 9-month follow-up, 
the restenosis rate as well as repeat revascularization rate was 
signiﬁ  cantly lower in the PES group than in the BMS group 
(31.2% and 10.4% [PES] versus 49.4% and 21.5% [BMS]; 
p = 0.01 and 0.03, respectively), although both parameters in 
the PES group were still high. In this underpowered posthoc 
analysis, numerical differences in the 9-month MACE rate 
between both treatment groups did not reach statistical 
signiﬁ  cance (18.9% [PES] versus 26.9% [BMS]; p = 0.23). 
Table 1  An overview of the TAXUS trials
  TAXUS I  TAXUS II  TAXUS III
  (Grube et al 2003)  (Colombo et al 2003)  (Tanabe et al 2003)
Published year 2003  2003  2003
Trial design Randomized  Randomized  Single  arm
Used device  TAXUS NIRx  TAXUS NIRx  TAXUS NIRx
Release kinetics  SR  SR and MR  SR
Patient number  TAXUS 31  TAXUS SR 131, SR control 136  TAXUS 28
  Control 30  TAXUS MR 135, MR control 134 
Lesion morphology  Single de novo or restenotic lesion  Single de novo lesion in  In-stent restenosis in
  in a native coronary artery  a native coronary artery  a native coronary artery
      with evidence of ischemia
Lesion length  = 12 mm  = 12 mm  = 30 mm
Vessel diameter  3.0 to 3.5 mm  3.0 to 3.5 mm  3.0 to 3.5 mm
Primary endpoint  MACE at 30 days  Mean % stent volume obstructed   N/A
    by neointimal proliferation 
    measured by IVUS at 6 months 
  TAXUS IV  TAXUS V  TAXUS VI
  (Stone et al 2004a)  (Stone et al 2005)  (Dawkins et al 2005)
Published year 2004  2005  2005
Trial design Randomized  Randomized  Randomized
Used device  TAXUS EXPRESS  TAXUS EXPRESS2 TAXUS  EXPRESS2
Release kinetics SR  SR  MR
Patient number  TAXUS 662   TAXUS 577  TAXUS 219
  Control 652  Control 579  Control 227
Lesion morphology  Single de novo lesion in  Single de novo lesion in  De novo lesion within
  a native coronary artery  a native coronary artery  a single native coronary artery
Lesion length  10 to 28 mm  10 to 46 mm  18 to 40 mm
Vessel diameter  2.5 to 3.75 mm  2.25 to 4.0 mm  2.5 to 3.75 mm
Primary endpoint  Ischemia driven TVR at 9 months  Ischemia driven TVR at 9 months  TVR at 9 months
IVUS, intravascular ultrasound; MACE, major adverse cardiac events; N/A, not available; MR, moderate release; SR, slow release; TVR, target vessel revascularization.Vascular Health and Risk Management 2007:3(4) 484
Tanimoto et al
Of note, the rate of periprocedural MIs in the PES arm was 
numerically higher than in the BMS arm without any statisti-
cal signiﬁ  cance (5.7% versus 2.2%, p = 0.27). Designed as 
a trial assessing outcomes in more complex lesions, most 
of the affected patients were characterized by an overlap of 
multiple complexities such as treatment of longer lesions in 
smaller vessels often with multiple overlapping stents.
TAXUS VI trial
In the TAXUS VI trial (Dawkins 2005), angiographic and 
clinical outcomes were followed up to 9 months. Some 
subgroup analyses were performed per classic risk factors 
for restenosis, including clinical outcomes in patients with 
small vessels (RVD  2.5 mm). In this subgroup, in-stent late 
lumen loss was considerably smaller in the PES group than 
in the BMS group (PES, 0.23 ± 0.45 mm versus BMS, 0.95 ± 
0.52 mm; p   0.0001), explaining the signiﬁ  cantly lower 
angiographic restenosis observed in the PES group (7.3% 
[PES] versus 40.4% [BMS]; p   0.0001). The incidence of 
TLR was also signiﬁ  cantly lower in the PES group (5.0% 
[PES] versus 29.7% [BMS]; p = 0.0003).
Taking these results into the consideration, PES seems to 
confer clinical beneﬁ  t in patients with small vessels compared 
to BMS. As shown in angiographic assessments, PES mark-
edly inhibit in-stent and in-segment (including implanted 
stent and 5 mm distal and proximal to the stent) neointimal 
hyperplasia, contributing to the signiﬁ  cantly lower TLR rate 
observed in these patients (see Table 2). To date, however, 
PES implantation in small vessels has not been studied pro-
spectively in a dedicated study. Only subgroup analysis data 
exist and the number of study patients is very small. Future 
multicenter randomized trials with large sample size, which 
focus on patients treated with PES for small vessel CAD, are 
required to better understand whether PES is more effective 
in patients with small vessels than BMS.
SES versus BMS in small vessels
SES is another commercially available DES promising 
improved clinical and angiographic results in patients with 
small vessel disease as compared to BMS. In contrast to 
paclitaxel, only a single stent type coated with one speciﬁ  c 
dose formulation for controlled release of sirolimus has been 
Table 2 Clinical and angiographic results in patients with small vessel disease in the TAXUS trials
  TAXUS IV subanalysis   TAXUS V subanalysis   TAXUS VI subanalysis 
  RVD <2.5 mm  2.25 mm stent implantation  RVD <2.5 mm
  (Stone et al 2004a, 2004b)  (Stone et al 2005)  (Dawkins et al 2005)
  PES  BMS  p value  PES  BMS  p value  PES  BMS  p value
Clinical outcomes                
Acute phase        30  days     
Death       0  0       
MI       5.6%  1.1%  0.12     
TLR       0.9%  1.1%  1.00     
TVR       1.9%  2.1%  1.00     
MACE       5.6%  2.1%  0.29     
Stent thrombosis        0.9%  1.1%  1.00     
Follow up     12 months    9 months      9 months
Death       1.9%  1.1%  1.00     
MI       5.7%  2.2%  0.29     
TLR 5.6%  20.6%  <0.0001  10.4%  21.5%  0.03  5.0%  29.7%  0.0003
TVR       16.0%  24.7%  0.16     
MACE       18.9%  26.9%  0.23     
Stent thrombosis        1.0%  1.1%  1.00     
Baseline QCA                
RVD        2.07 ± 0.31  2.10 ± 0.33  0.46     
Lesion length        16.6 ± 9.7  16.4 ± 9.2  0.91     
Follow-up QCA    9 months      9 months      9 months
Late Loss (instent)        0.49 ± 0.61  0.90 ± 0.63  <0.001  0.23 ± 0.45   0.95 ± 0.52  <0.0001
Late Loss (segment)        0.36 ± 0.53  0.61 ± 0.59  0.004     
Restenosis (instent)        24.7%  44.7%  0.007  7.3%  40.4%  <0.0001
Restenosis (segment)  10.2%  38.5%  <0.001  31.2%  49.4%  0.01     
BMS, bare metal stent; MACE, major adverse cardiac events; MI, myocardial infarction; PES, paclitaxel-eluting stent; QCA, quantitative coronary angiography; RVD, reference 
vessel diameter; TLR, target lesion revascularization; TVR, target vessel revascularization.Vascular Health and Risk Management 2007:3(4) 485
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investigated over the last several years: the SES consists of 
the Bx Velocity stent loaded with 1.4 ug/mm2 sirolimus. Siro-
limus is a macrolide with immunosuppressive, antiprolifera-
tive and antifungal properties. Different from the mechanism 
of paclitaxel, sirolimus prevents progression from the G1 
phase (cell growth) to the S phase (DNA replication), result-
ing in inhibition of the growth of vascular smooth muscle 
cells, which is a major process of in-stent restenosis.
The SIRIUS trial showed that SES had a signiﬁ  cant lower 
1-year TLR rate than BMS in patients with RVD  2.75 mm 
(6.6% [SES] versus 22.3% [BMS]; p   0.0001) (Holmes 
et al 2004). In an angiographic substudy of the SIRIUS trial 
(Popma et al), patients were categorized into tertiles accord-
ing to RVD and angiographic outcomes between SES and 
BMS were assessed. The smallest tertile had mean RVD of 
2.32 mm in the SES group and 2.31 mm in the BMS group 
(p = 0.683). Angiographic restenosis rate in the SES group 
was signiﬁ  cantly lower than in the BMS group (17.6% vs 
42.7%, p   0.001). The SES-SMART trial (Ardisso et al 
2004), which enrolled patients with small vessels (mean RVD 
2.2mm), indicated that the incidence of TLR and MACE in 
the SES arm was 7.0% and 9.3% versus 21.1% and 31.3% 
in the BMS arm (p = 0.002 and p   0.001, respectively). In 
addition, angiographic restenosis rate in the SES arm was 
also signiﬁ  cantly lower compared to the BMS arm (9.8% vs 
53.1 %, p   0.001).
These results indicated that SES is no less effective than 
PES in patients with small vessel CAD. However, which 
DES is superior to the other in small vessel stenting still 
remains controversial.
PES versus SES in small vessels
Several recent trials (de Lezo et al 2005; Kastrati et al 2005a; 
Dibra et al 2005; Windecker et al 2005; Goy et al 2005; 
Morice et al 2006) and a meta-analysis (Kastrati et al 2005b) 
have compared PES with SES. While suggesting advantages 
of SES in reducing neointimal hyperplasia, many of the 
comparative trials have been limited by inadequate sample 
size, execution in single center, and use of institutional rather 
than independent core labs and event committees limiting the 
acceptability of these datasets for establishment of formal 
treatment guidelines. Indeed, when these comparative trials 
are scored by Silver score (Silber 2005) (see Table 3), which 
rate the level of evidence provided by the various DES trials 
(range from 0 to 10) and intend to help physicians evaluate 
the strength of evidence, calculated scores are relatively low 
(high scores can be considered strong evidence): CORPAL 
study (de Lezo et al 2005) is 1, ISAR-DESIRE (Kastrati 
et al 2005a) 4, ISAR-DIABETES(Dibra et al 2005) 4, SIR-
TAX (Windecker et al 2005) 6, TAXi (Goy et al 2005) 5 
and REALITY (Morice et al 2006) 4. In addition, there is 
limited information on the relative efﬁ  cacy and safety of 
PES compared to SES in patients with small vessel disease. 
Only 3 trials were reported: 1 randomized trial and 2 non-
randomized trials (see Table 4). We describe these 3 trials 
in the section below.
Table 3 Silver score system
Evaluation Parameter  Possible points
Clinical Primary Endpoint (TLR, TVR, TVF, MACE)  Yes = 3
  No = 0
Double-Blind (including physicians)  Yes = 1
  No = 0
Evaluation Interval of Primary Endpoint ≥6 Months  Yes = 1
  No = 0
Multi-Center (at least 3 centers)  Yes = 1
  No = 0
Clinical Events Committee/Data Safety Monitoring Board Independent and External from Steering Committee  Yes = 1
  No = 0
Primary Endpoint Reached  Yes = 1
  No = 0
Power of ≥80% for Primary Endpoint Achieved  Yes = 1
  No = 0
Follow-up Percentage ≥80% for Angiographic Primary Endpoint or Follow-up Percentage of ≥95% for Clinical Primary Endpoint  Yes = 1
  No = 0
Maximum Silber Score  10
Minimum Silber Score  0
TLR, target lesion revascularization; TVF, target vessel failure; TVR, target vessel revascularization; MACE, major adverse cardiac events. Vascular Health and Risk Management 2007:3(4) 486
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The ISAR-SMART 3 trial was a first head-to-head 
comparative (PES vs SES) randomized trial for patients 
with small vessel disease (mean RVD was about 2.4 mm) 
(Mehilli et al 2006). Angiographic and clinical outcomes 
were followed up to 8 months. SES was more effective in 
reducing restenosis and TLR than PES (11.4 and 6.6% in the 
SES group vs 19.0 and 14.7% in the PES group, p = 0.047 
and 0.008, respectively). These results indicated that PES 
induced a greater late lumen loss and were less effective in 
reducing restenosis in small coronary vessels as compared 
to SES. Consequently, SES was associated with a lower 
incidence of angiographic restenosis as well as a reduced 
need of repeat revascularization.
There were 2 additional non-randomized trials com-
paring the efficacy between PES and SES in patients 
with small vessel disease. One was a study of Park et al 
, which was a retrospective study including 197 patients 
with a mean RVD of nearly 2.45 mm (Park et al 2006) . 
Angiographic restenosis rate at 6 months and TLR rate 
at 9 months were 6.7 and 3.3% in the SES group, while 
27.7 and 14.4% in the PES group (p < 0.01 and < 0.01, 
respectively).
Table 4 Clinical and angiographic results of the studies comparing PES to SES implantation in patients with small vessel disease
            RESEARCH  and  T -SEARCH
 ISAR-SMART  3    Park  et  al      subanalysis
  (Mehilli et al 2006)    (Park et al 2006)    (Rodriguez-Granillo et al 2005; 
          Tanimoto  et  al  2006)
   SES  PES  p value  SES  PES  p value  SES  PES  p value
Patient number  n = 180  n = 180     n = 121  n = 76     n = 107  n = 92   
Trial design  Randomized trial    Non-randomized trial    Non-randomized trial
Clinical outcomes                 
Acute phase  30 days      In hospital      30 days
Death         0%  0%  1  0.9%  2.2%  0.59
MI  3.9%  3.3%  0.78 12.4%  13.2%  0.54 2.8%  6.7%  0.31
TLR  0% 0.6%  0.32  0% 0% 1  2.8%  5.6%  0.47
TVR              2.8%  5.6%  0.47
MACE         12.4%  13.2%  0.54  4.7%  12.2%  0.07
Stent  thrombosis  0% 0% >0.99  0% 0% 1  0% 2.2%  0.21
Follow up  12 months      9 months      12 months
Death 1.7%  2.2%  >0.99  0%  0%  1  0.9%  4.3%  0.18
MI  3.9%  3.3%  0.78 12.4%  13.2%  0.54 2.8%  7.8%  0.19
TLR  6.6%  14.7% 0.008  3.3%  14.4% <0.01  6.5%  11.1%  0.31
TVR              7.5%  12.2%  0.33
MACE         15.7%  27.6%  <0.01  9.3%  18.9%  0.06
Stent thrombosis                0%  2.2%  0.21
Baseline QCA                      
RVD  2.44 ± 0.34  2.40 ± 0.38  0.34  2.47 ± 0.21  2.44 ± 0.25  0.19  1.86 ± 0.37  1.95 ± 0.38  0.15
MLD  0.99 ± 0.40  1.03 ± 0.39  0.33  0.86 ± 0.33  0.81 ± 0.42  0.31  0.47 ± 0.38  0.57 ± 0.38  0.06
DS  59.4 ± 15.3  57.2 ± 14.4  0.15  65.4 ± 13.0  67.5 ± 16.0  0.22  74.8 ± 20.1  70.3 ± 19.3  0.10
Lesion length  12.9 ± 8.0  11.7 ± 6.7  0.12  25.2 ± 14.7  27.1 ± 12.7  0.34  13.0 ± 8.5  16.4 ± 10.4  0.02
Post-PCI QCA                      
MLD (instent)  2.44 ± 0.36  2.44 ± 0.37  0.8         1.73 ± 0.31  1.82 ± 0.36  0.06
MLD (segment)  2.04 ± 0.47  2.00 ± 0.47  0.41  2.52 ± 0.33  2.42 ± 0.35  0.45  12.3 ± 10.0  14.0 ± 9.8  0.19
DS (instent)  5.6 ± 7.5  6.3 ± 7.7  0.36              
DS (segment)  16.7 ± 7.7  18.5 ± 7.2  0.05  3.7 ± 7.1  5.8 ± 8.3  0.06       
Follow-up QCA  6  months     6  months      
MLD (instent)  2.21 ± 0.66  1.88 ± 0.67  <0.001              
MLD (segment)  1.91 ± 0.61  1.67 ± 0.63  <0.001  2.32 ± 0.56  1.77 ± 0.77  <0.01       
DS (instent)  17.2 ± 21.5  26.7 ± 21.8  <0.001              
DS (segment)  28.4 ± 19.7  35.0 ± 20.6  <0.002  5.38 ± 22.5  31.7 ± 34.9  <0.01       
Late loss (instent)  0.25 ± 0.55  0.56 ± 0.59  <0.001              
Late loss (segment)  0.13 ± 0.56  0.34 ± 0.57  <0.001  0.29 ± 0.42  0.69 ± 0.62  <0.01       
Restenosis (instent)  8.0%  14.9%  0.04              
Restenosis  (segment)  11.4% 19.0% 0.047  6.7%  27.7% <0.01       
DS, diameter stenosis; MACE, major adverse cardiac events; MI, myocardial infarction; MLD, minimal lumen diameter; PES, paclitaxel-eluting stent; QCA, quantitative coro-
nary angiography; RVD, reference vessel diameter; SES, sirolimus-eluting stent; TLR, target lesion revascularization; TVR, target vessel revascularization.Vascular Health and Risk Management 2007:3(4) 487
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Another was a substudy of the RESEARCH and 
T-SEARCH registries, which adopted a non-randomized 
design (Rodoriguez-Granillo et al 2005, Tanimoto et al 2006). 
This substudy was the only 1 investigating long-term follow-
up (up to 2 years) of patients treated with PES or SES in small 
coronary vessels. Patients treated with 2.25 mm diameter PES 
or SES were evaluated in terms of clinical outcomes without 
systematic angiographic follow-up and therefore evaluated 
only clinical beneﬁ  t. The incidence of 1 year TLR and MACE 
was numerically more frequent in the PES group, but they 
did not reach statistical difference (11.1 and 18.9% vs 6.5 
and 9.3% in the SES group; p = 0.31 and 0.06, respectively). 
TLR at 2 years was observed more frequently in the PES 
group (12.2% vs 6.5% in the SES group, p = 0.22); only 1 
patient in the PES arm underwent repeat revascularization 
in the second year. The 2-year MACE rate was signiﬁ  cantly 
higher in the PES group than in the SES group (23.3% vs 
10.3%, p = 0.02).
Considering these results, SES has been implied to offer 
slight advantages over PES in small vessel stenting regarding 
angiographic and sometimes even clinical outcomes. 
Nevertheless, the root cause for such differences between 
PES and SES remains unclear. The mechanical differences 
of both DES may affect angiographic restenosis as a study 
of Briguori et al which showed that strut thickness was an 
independent predictor of angiographic restenosis in small 
coronary arteries (RVD of 2.75 to 2.99 mm); thinner-strutted 
stents were associated with lower incidence of restenosis 
than thicker-strutted stents (Briguori et al 2002). But the strut 
thicknesses of PES and SES are very similar (0.132 mm and 
0.140 mm, respectively) so that such a mechanical property 
does not inﬂ  uence the result of angiographic outcomes 
obtained by both DES implantations. Different mechanisms 
of inhibiting neointimal hyperplasia and drug-release kinetics 
between PES and SES presumably accounts for the observed 
difference in their performance.
At the moment, however, it is difficult to conclude 
that SES is superior to PES in small vessel stenting. It is 
underscored that to date only one randomized controlled trial 
(ISAR-SMART 3) was performed to compare differences 
between PES and SES in small vessel stenting. This 
randomized study was open-labeled trial and was conducted 
at only 2 investigative sites, therefore the Silver score is 3 out 
of 10. In addition, this study excluded patients with diabetes 
mellitus, which was a famous independent predictor leading 
to worse angiographic and clinical outcomes. Moreover, the 
number of enrolled patients in each study was too small and 
underpowered to deﬁ  nitely assess the effectiveness of both 
DES for small coronary artery lesions regarding with TLR, 
TVR or MACE. The other 2 trials comparing the efﬁ  cacy of 
PES and SES in small vessels were non-randomized studies 
so that their strength of evidence were low. Inclusion and 
exclusion criteria of each study varied. It must be noted that 
larger, multicenter (at least  3), randomized, blinded trials, 
with a deﬁ  ned clinical endpoint in patients with small vessels 
are required to ﬁ  rmly determine a clinical advantage of one 
DES over the other. As of present, limited results from these 
3 trials do not conﬁ  rm a signiﬁ  cant advantage of SES over 
PES in this patient population.
Safety concern of small vessel DES 
stenting
After DES were approved, these devices have been implanted 
in a large number of patients with CAD including several 
kinds of clinical and anatomic situations such as acute MI, 
bifurcation lesions and overlapping stent deployment. Their 
use seems to be feasible and safe. Recently, however, certain 
potential issues have been raised.
One of the issues is stent thrombosis. Although rare, some 
studies have cautioned that as compared to BMS, either PES 
or SES could increase the incidence of this complication, 
especially that of late stent thrombosis (occurring >30 days 
after stent placement) (McFadden et al 2004; Iakovou et al 
2005; Ong et al 2005; Moreno et al 2005). Increased risk for 
thrombosis may be associated with the decreased endothelial 
function (Hofma et al 2006), and/or delayed vascular heal-
ing (Degertekin et al 2002; Guagliumi et al 2003; Joner et al 
2006) induced with DES. In addition, hypersensitivity reac-
tions to the polymer coating of the DES and the drug itself 
may also contribute to stent thrombosis (Virmani et al 2004; 
Nebeker et al 2006). Although BMS implantation in small 
vessels had been previously cited as a risk factor for stent 
thrombosis (Karrillon et al 1996; Mak et al 1996; Moussa 
1997), improved techniques of optimal stent deployment and 
dual antiplatelet regimens appear to have largely resolved 
this problem so that the risk of stent thrombosis of BMS 
in small vessel stenting now seems to be similar to that in 
larger vessel stenting (Akiyama 1998; Lau et al 2000). But, 
DES implantation in small vessels may increase the risk 
of stent thrombosis because of their features as mentioned 
above. The incidence of stent thrombosis in small vessel 
DES stenting has not been shown to differ between PES and 
BMS or SES. In a subanalysis conducted in the TAXUS V 
clinical trial, both acute and late stent thrombosis rate were 
similar between PES and BMS (0.9% versus 1.1% and 1.0 % 
versus 1.1%, p = 1.00 and 1.00, respectively) (Table 2). In Vascular Health and Risk Management 2007:3(4) 488
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the ISAR-SMART 3 trial and a study of Park et al, no acute 
stent thrombosis was reported in both the SES and PES arms, 
while there was no information about late stent thrombosis in 
either trial (see Table 4). In a subanalysis of the RESEARCH 
and T-SEARCH registries, 2.2% of patients had acute stent 
thromboses in the PES arm; no thrombosis was observed in 
the SES arm (see also Table 4). This observation was not 
signiﬁ  cant (p = 0.21). No late stent thrombosis occurred 
in either arm. It should be mentioned that the deﬁ  nition of 
stent thrombosis varied (clinical or angiographic) and treated 
lesion type differed among clinical trials. In addition, though 
most trials reported their outcomes within 1 year, late stent 
thrombosis often occurred more than 1 year after DES place-
ment. To better understand this adverse event, a much larger 
sample size and longer-term follow-up are warranted.
Delayed restenosis, which is also called a “late catch-up 
phenomenon”, is another issue after DES deployment. This 
event was ﬁ  rst observed in the porcine model (Farb et al 2001; 
Carter et al 2004). Also in humans, continued neointimal 
growth of during the follow-up period was noted in some tri-
als in which serial intravascular ultrasound (IVUS) analyses 
were performed (Aoki et al 2005a; Aoki et al 2005b; Aoki 
et al 2005c). The precise reason for this phenomenon is still 
unclear. Delayed neointimal hyperplasia could lead to higher 
incidence rates of TLR and MACE observed during long-term 
follow-up. This is especially relevant with small vessel DES 
stenting, since even a small volume of neointimal tissue can 
affect the incidence of angiographic restenosis by virtue of 
the smaller RVD. With respect to small vessel stenting, few 
long-term follow-up data exist (Table 5). In a subanalysis of 
the SIRIUS 2-year outcomes (Weisz et al 2006), TLR rate in 
the second year was 1.7% in the SES group and 0.8% in the 
BMS group (p = 0.17). In a substudy of the RESEARCH and 
T-SEARCH registries, only 1 patient (1.1%) treated with PES 
presented with TLR in the second year (0% in the SES arm, p 
= 0.46). In these 2 studies, angiographic parameters were not 
reported, thus the increase of neointima was unknown during 
the second year. However, according to these results, it may 
be inferred that if late catch-up phenomenon occurred after 
small vessel DES stenting, its effect might be restrictive in 
this clinical setting. The efﬁ  cacy of DES was ascertained up 
to 2-years even in treatment of small vessel CAD.
Table 5 Long-term clinical follow-up trials in small vessel DES stenting
   SIRIUS subanalysis     RESEARCH and T -SEARCH
  RVD < 2.75 mm      subanalysis
  (Weisz et al 2006)     (Tanimoto et al 2006)
   SES  BMS  p value  SES  PES  p value
Patient number  n = 533  n = 525     n = 107  n = 92   
Trial design  Randomized trial      Non-randomized trial
1-year follow up          
death         0.9%  4.3%  0.18
MI         2.8%  7.8%  0.19
TLR 6.6%  22.3%  <0.0001  6.5%  11.1%  0.31
TVR         7.5%  12.2%  0.33
MACE         9.3%  18.9%  0.06
Stent thrombosis         0%  2.2%  0.21
2-year follow up          
death         1.9%  7.6%  0.08
MI         2.8%  7.6%  0.19
TLR 8.3%  23.0%  <0.0001  6.5%  12.2%  0.22
TVR         7.5%  13.3%  0.24
MACE         10.3%  23.3%  0.02
Stent thrombosis         0%  2.2%  0.21
1-year to 2-year              
death         0.9%  3.3%  0.33
MI         0%  0%   
TLR 1.7%  0.8%  0.17  0%  1.1%  0.46
TVR         0%  1.1%  0.46
MACE         0.9%  4.3%  0.18
Stent thrombosis         0%  0%   
BMS, bare metal stent; MI, myocardial infarction; MACE, major adverse cardiac events; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; TLR, target lesion revascular-
ization; TVR, target vessel revascularization.Vascular Health and Risk Management 2007:3(4) 489
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At present, small vessel stenting by using either PES or 
SES seems to be safe and does not increase adverse cardiac 
events in short- and medium-term follow-up. However, 
long-term follow-up and larger sample multicenter studies 
are needed to determine whether DES implantation is safe 
in patients with small vessel CAD.
Conclusion
In this manuscript, we reviewed the placement of BMS, 
PES, and SES in small vessels with respect to efﬁ  cacy and 
safety. At present, the following general conclusions about 
small vessel stenting can be made: (1) PES considerably 
reduce the incidence of angiographic restenosis and TLR 
as compared to BMS; (2) a trend is observed with regard 
to better angiographic and clinical outcomes of SES over 
PES, but there is little and weak information to support this 
result; and (3) Both PES and SES seem to be safe and don’t 
increase severe cardiac complication, such as acute and late 
stent thrombosis.
Even in the DES era, small RVD is still an independent pre-
dictor of angiographic and clinical restenosis (Kastrati 2006). 
However, there are a very limited number of studies focusing 
on small vessel DES stenting. Therefore, large-sample size, 
double-blinded, randomized-controlled multicenter trials with 
long-term follow-up and a clinical primary endpoint are needed 
to establish the fact that both PES and SES are effective and 
safe in small vessel coronary disease.
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